𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Spectrum of ADL impairment and response to rivastigmine varies by severity of alzheimer's disease

✍ Scribed by Messina, John C.; Graham, Stephen; Potkin, Steven G.


Book ID
122739784
Publisher
Elsevier Science
Year
2000
Tongue
English
Weight
194 KB
Volume
21
Category
Article
ISSN
0197-4580

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Rivastigmine transdermal patch and capsu
✍ Martin R. Farlow; George T. Grossberg; Xiangyi Meng; Jason Olin; Monique Somogyi πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 373 KB

## Abstract ## Objectives The cholinesterase inhibitor rivastigmine is approved for the symptomatic treatment of mild to moderate Alzheimer's disease (AD). This exploratory, hypothesis‐forming analysis assessed response to rivastigmine according to severity of dementia at baseline. ## Methods Th